Arabian International Healthcare Holding Company (9530) fair value: what the stock is really worth
We calculate from audited financials what Arabian International Healthcare Holding Company is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Arabian International Healthcare Holding Company for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
54‑month range 16.60 SAR – 76.80 SAR · fair‑value band 8.18 SAR – 28.12 SAR · the 16.90 SAR price screens below the 17.51 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Arabian International Healthcare Holding Company engages in distribution and maintenance of medical, devices, imaging equipment, prosthetics, dental and veterinary equipment, and cosmetic products in the Kingdom of Saudi Arabia. It operates through Medical Supplies and Medical Equipment segments.
Show more
Arabian International Healthcare Holding Company engages in distribution and maintenance of medical, devices, imaging equipment, prosthetics, dental and veterinary equipment, and cosmetic products in the Kingdom of Saudi Arabia. It operates through Medical Supplies and Medical Equipment segments. The company offers various products for cardiology, intensive care, oncology, rehab, infection prevention technologies, hospital infrastructure, gene sequencing laboratory, anesthesia machines, hospital beds and medical furniture, lab furniture solution, biobanking solution, hospital information technology, surgical rooms solutions, laboratories, and ventilation system. It also provides its products for orthopedics, management delivery solutions, catheters and syringes, and vein thrombosis prevention. In addition, the company offers medical services at clinics; and sells health and beauty related medicines. Arabian International Healthcare Holding Company was founded in 1973 and is headquartered in Riyadh, Saudi Arabia.
Stock analysis
Arabian International Healthcare Holding Company (9530) currently trades at 16.90 SAR, while our model-based Fair Value estimate is 17.51 SAR, implying the stock looks roughly 3.5% fairly valued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 26.45 SAR per share, and 13 of the 22 models we run sit above the 16.90 SAR price.
Bear case: the Dividend Discount group reads lowest at 6.82 SAR, and 9 of the 22 models stay below the price. Evidence for this calculation is high.
Scenario range: 8.18 SAR (bear) to 28.12 SAR (bull), the price of 16.90 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Arabian International Healthcare Holding Company reported revenue of 842M SAR in FY2025 versus 619M SAR in FY2021, a compound +8.0%/yr. Reported net income was 23.8M SAR in FY2025, compounding −26.7%/yr from FY2021.
Key figures
Market cap 383M SAR (≈ $102M) · P/E ratio 11.6 · P/S ratio 0.33 · EPS (TTM) 1.44 SAR · Dividend yield 3.2% · Net margin 2.8% · Return on equity 8.7% · Return on assets (EBIT) 4.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 0% fair-value upside, at 4%, 9530 screens cheaper than that median.
Fair Value models
Bear 8.18 SARFair Value 17.51 SARBull 28.12 SAR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (1.01 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+3.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−18.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−21.8%
Dividend (yield on the price)3.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 8%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+47.9%
Yearly growth needed for the next five years to justify today's price.
Compare Arabian International Healthcare Holding Company with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 255 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside+17% · Above median
Profitability
Return on equity (TTM)9% · Above median
Return on assets4% · Below median
Net margin (TTM)3% · Below median
Operating margin (TTM)9% · Below median
Growth and dividend
Revenue growth27% · Top 25%
Dividend yield (TTM)3.2% · Above median
Balance sheet
Debt / equity0.24× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Arabian International Healthcare Holding Company Fair Value". https://www.fairvalue-calculator.com/stock/9530
Frequently asked questions
Is Arabian International Healthcare Holding Company (9530) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 17.51 SAR versus a price of 16.90 SAR, about +4% upside (fairly valued).
What is the fair value of 9530?
Our model-based fair value for Arabian International Healthcare Holding Company is 17.51 SAR (as of Sep 13, 2026), built from audited fundamentals. The current price: 16.90 SAR.
What is the quality score of 9530?
Arabian International Healthcare Holding Company has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Arabian International Healthcare Holding Company (9530)?
Our model-based price target is the fair value of 17.51 SAR (as of Sep 13, 2026) from 24 valuation models. Cautious scenario 8.18 SAR, optimistic scenario 28.12 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Arabian International Healthcare Holding Company stock forecast for 2026?
Our models put fair value at 17.51 SAR, about +4% upside versus a price of 16.90 SAR (fairly valued). Cautious scenario 8.18 SAR, optimistic scenario 28.12 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Arabian International Healthcare Holding Company (9530)?
Arabian International Healthcare Holding Company reported trailing-twelve-month revenue of about 842M SAR (latest available figure, as of Sep 13, 2026).
Does Arabian International Healthcare Holding Company pay a dividend?
Arabian International Healthcare Holding Company currently shows a dividend yield of about 3.20% relative to its recent price (as of Sep 13, 2026).
What growth is priced into Arabian International Healthcare Holding Company (9530)?
For today's price to be fair in a discounted-cash-flow model, Arabian International Healthcare Holding Company would have to grow free cash flow by +47.9 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.6 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of 9530 use?
Our models discount Arabian International Healthcare Holding Company at 11.8 %: a base by market capitalisation (micro), damped by beta 0.18, country premium for Saudi Arabia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Arabian International Healthcare Holding Company that is +47.9 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Arabian International Healthcare Holding Company (9530) delivered so far?
Over the past 5 years revenue at Arabian International Healthcare Holding Company grew +0.6 % a year. The price currently implies +47.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Arabian International Healthcare Holding Company (9530) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Arabian International Healthcare Holding Company (+47.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Arabian International Healthcare Holding Company (9530)?
The free-cash-flow yield on the price is 1.90 %: that much free cash flow Arabian International Healthcare Holding Company produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Arabian International Healthcare Holding Company (9530)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Arabian International Healthcare Holding Company it is 17.51 SAR per share (as of Sep 13, 2026), against a price of 16.90 SAR. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Arabian International Healthcare Holding Company stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 9530 trades below its calculated fair value: price 16.90 SAR, fair value 17.51 SAR, a gap of about +4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9530?
No. The price is what the market pays today (16.90 SAR); the fair value is what the company's own numbers justify (17.51 SAR). For Arabian International Healthcare Holding Company the two are 0.6100 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Arabian International Healthcare Holding Company worth?
The market values Arabian International Healthcare Holding Company at about 383M SAR (market capitalisation, as of Sep 13, 2026). Per share that is 16.90 SAR; our models calculate a fair value of 17.51 SAR per share.
What do the bullish and bearish scenarios say about 9530?
Our models span a range for Arabian International Healthcare Holding Company: cautious scenario 8.18 SAR, base 17.51 SAR, optimistic 28.12 SAR per share (as of Sep 13, 2026, price 16.90 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9530?
Arabian International Healthcare Holding Company trades at a price-to-earnings ratio of 11.6 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 17.51 SAR is built from several models across several years. Other multiples: P/B 0.3, P/S 0.1, EV/EBITDA 2.2.
How solid is the balance sheet of Arabian International Healthcare Holding Company (9530)?
Balance-sheet figures for Arabian International Healthcare Holding Company (as of Sep 13, 2026): return on equity 8.7%, debt of 0.24 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 9530 from its 52-week high?
Arabian International Healthcare Holding Company trades at 16.90 SAR, about 53% below its 52-week high of 36.00 SAR (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 17.51 SAR is for.
Which stocks are comparable to Arabian International Healthcare Holding Company?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Arabian International Healthcare Holding Company stock attractive at the current price?
The data as of Sep 13, 2026: price 16.90 SAR, calculated fair value 17.51 SAR (+4%), Quality Score 50/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9530 calculated?
We run Arabian International Healthcare Holding Company through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 17.51 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Arabian International Healthcare Holding Company currently trades 4 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Arabian International Healthcare Holding Company right now?
The model range is unusually wide (8.18 SAR to 28.12 SAR). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Key figures of Arabian International Healthcare Holding Company
How large is the market capitalisation of Arabian International Healthcare Holding Company (9530)?
The market capitalisation of Arabian International Healthcare Holding Company is 383M SAR (≈ $102M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Arabian International Healthcare Holding Company (9530)?
The price-to-sales ratio of Arabian International Healthcare Holding Company is 0.33 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Arabian International Healthcare Holding Company (9530)?
Earnings per share at Arabian International Healthcare Holding Company are 1.44 SAR (price ÷ EPS = P/E 11.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Arabian International Healthcare Holding Company (9530)?
The dividend yield of Arabian International Healthcare Holding Company is 3.2% (payout 37.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Arabian International Healthcare Holding Company (9530)?
The net margin of Arabian International Healthcare Holding Company is 2.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Arabian International Healthcare Holding Company (9530)?
The return on equity (ROE) of Arabian International Healthcare Holding Company is 8.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Arabian International Healthcare Holding Company (9530)?
On an EBIT basis the return on assets of Arabian International Healthcare Holding Company is 4.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Arabian International Healthcare Holding Company (9530)?
The operating margin of Arabian International Healthcare Holding Company is 9.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Arabian International Healthcare Holding Company (9530)?
Revenue at Arabian International Healthcare Holding Company is growing +27.3% versus a year earlier (3y avg +9.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Arabian International Healthcare Holding Company (9530)?
Earnings per share at Arabian International Healthcare Holding Company are growing +49.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Arabian International Healthcare Holding Company (9530) carry?
The net debt of Arabian International Healthcare Holding Company is 332M SAR (fiscal year 2025, ≈ 52.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Arabian International Healthcare Holding Company in the live analysis
One click puts Arabian International Healthcare Holding Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
